Strikingly, treatment with EA for only 2 weeks reduced the obesity-elevated leptin and insulin levels by 69.3% (Figure 5D) and 58.5% (Figure 5E), respectively, in obese mice, which is likely due to improved obesity and insulin resistance consistent with previous findings in this mouse model (37, 38). The gene discussed is LEP; the disease is Insulin resistance.